Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (331-340 of 1,833) with videos related to

Pageof 184
Sort By:
Mabs|June 14, 2014
Highly parallel characterization of IgG Fc binding interactionsAustin W Boesch, Eric P Brown, Hao D Cheng, et al.
Mabs|January 22, 2015
Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibodyLi Peng, Vaheh Oganesyan, Herren Wu, et al.
Mabs|August 7, 2012
Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritisPalanisamy Kanakaraj, Bridget A Puffer, Xiao-Tao Yao, et al.
Mabs|September 26, 2012
Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621Neil R Michaud, Jitesh P Jani, Stephen Hillerman, et al.
Mabs|June 16, 2012
Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycansMarcella Yu, Darren Brown, Chae Reed, et al.
Mabs|July 24, 2012
Peptibodies: A flexible alternative format to antibodiesGrant Shimamoto, Colin Gegg, Tom Boone, et al.
Mabs|July 24, 2012
Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodiesYi Du, Alison Walsh, Robin Ehrick, et al.
Mabs|July 24, 2012
CD19 as an attractive target for antibody-based therapyOhad Hammer
Mabs|July 24, 2012
The assay design used for measurement of therapeutic antibody concentrations can affect pharmacokinetic parameters: Case studiesSaloumeh K Fischer, Jihong Yang, Banmeet Anand, et al.
Mabs|March 23, 2010
Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1Mei-Yun Zhang, Andrew Rosa Borges, Roger G Ptak, et al.
Pageof 184

Showing results (331-340 of 1,833) with videos related to

Sort By:
Pageof 184
Mabs|June 14, 2014
Highly parallel characterization of IgG Fc binding interactionsAustin W Boesch, Eric P Brown, Hao D Cheng, et al.
Mabs|January 22, 2015
Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibodyLi Peng, Vaheh Oganesyan, Herren Wu, et al.
Mabs|August 7, 2012
Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritisPalanisamy Kanakaraj, Bridget A Puffer, Xiao-Tao Yao, et al.
Mabs|September 26, 2012
Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621Neil R Michaud, Jitesh P Jani, Stephen Hillerman, et al.
Mabs|June 16, 2012
Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycansMarcella Yu, Darren Brown, Chae Reed, et al.
Mabs|July 24, 2012
Peptibodies: A flexible alternative format to antibodiesGrant Shimamoto, Colin Gegg, Tom Boone, et al.
Mabs|July 24, 2012
Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodiesYi Du, Alison Walsh, Robin Ehrick, et al.
Mabs|July 24, 2012
CD19 as an attractive target for antibody-based therapyOhad Hammer
Mabs|July 24, 2012
The assay design used for measurement of therapeutic antibody concentrations can affect pharmacokinetic parameters: Case studiesSaloumeh K Fischer, Jihong Yang, Banmeet Anand, et al.
Mabs|March 23, 2010
Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1Mei-Yun Zhang, Andrew Rosa Borges, Roger G Ptak, et al.
Pageof 184